



**29 September 2021**

## ASX Announcement

### **Date of AGM & Closing Date for Director Nominations**

MELBOURNE Australia, 29 September 2021: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held virtually on Wednesday, 17 November 2021. The Company will follow the measures in place as set by the Australian and Victorian governments for the restriction of gatherings and the implementation of social distancing requirements in response to COVID-19.

An item of business at the AGM will be the re-election of Directors. In accordance with clause 13.3 of the Company's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Wednesday, 6 October 2021.

Any nominations must be received by the Company in writing by no later than 5:00 pm (Melbourne time) on Wednesday, 6 October 2021.

#### **Approved for release to the ASX by:**

Dr Paul MacLeman  
Executive Chairman  
Island Pharmaceuticals  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

For further information, please contact:

<b>Investors:</b> Jane Lowe IR Department Mobile: +61 411 117 774 <a href="mailto:jane.lowe@irdepartment.com.au">jane.lowe@irdepartment.com.au</a>	<b>Media:</b> Juliana Roadley IR Department Mobile: +61 414 889 863 <a href="mailto:juliana.roadley@irdepartment.com.au">juliana.roadley@irdepartment.com.au</a>
--	--

#### **About Island Pharmaceuticals**

Island is clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, following a successful Phase III trial, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the



Priority Review Voucher (PRV) would permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.